Quantcast
 
Read Larry Connors' blogShort Term Trading Strategies


 

Invitrogen & Applied Biosystems Merge to Form Life Technologies; Fitch Rtd 'BBB-'

Mon. November 24, 2008; Posted: 02:05 PM
Stocks RSS
CHICAGO, Nov 24, 2008 (BUSINESS WIRE) -- IVGN | Quote | Chart | News | PowerRating -- On Nov. 21, 2008, Invitrogen Corp. and Applied Biosystems Inc. completed their previously announced merger to form a new company named Life Technologies Corp. In a press release dated Aug. 4, 2008, Fitch assigned the following ratings to the merged entity:

--Issuer Default Rating (IDR) 'BBB-';

--Senior convertible notes 'BBB-';

--Senior secured credit facilities 'BBB-'.

The Rating Outlook is Stable.

Life Technologies' ratings are supported by the company's strong cash flows, leading market position, diversified customer base and low capital expenditure needs. The company benefits from the recurring nature of its revenue stream (over 70% of total revenues are from consumables and services), strong customer loyalty, and the nature of its end markets (tied to general health care spending and biological research). Key ratings concerns center on integration risks post-merger as well as the high levels of debt and leverage expected. Fitch's ratings incorporate the expectation that the company will reduce debt over the next one to two years to a level more appropriate for the rating category (under 3.0 times (x)).

Fitch believes the complementary nature of the successor companies' product lines will enable the realization of revenue synergies post-merger. Life Technologies will be able to offer more bundled product solutions, including complementary instruments and reagents, which are increasingly important to life science researchers and applied markets customers. In addition, Fitch believes the company will have the opportunity to leverage existing customer channels (such as Invitrogen's Supply Centers) and complementary research & development projects to drive revenue growth. Facility rationalization, overhead reduction, and consolidation of marketing activities, among other activities, should lead to the realization of cost synergies as well. In addition, Fitch believes there is significant growth potential for the life sciences tools industry in general as well as the company's targeted market segments in particular (such as next-generation DNA sequencing).

Fitch's rating definitions and the terms of use of such ratings are available on the agency's public site, www.fitchratings.com. Published ratings, criteria and methodologies are available from this site, at all times. Fitch's code of conduct, confidentiality, conflicts of interest, affiliate firewall, compliance and other relevant policies and procedures are also available from the 'Code of Conduct' section of this site.

SOURCE: Fitch Ratings

Fitch Ratings, Chicago Lauren Coste, 312-606-2320 Mike Zbinovec, 312-368-3164 or Media Relations: Cindy Stoller, 212-908-0526, New York Email: cindy.stoller@fitchratings.com

For full details for IVGN click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [IVGN]
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.